The UK and US have signed a key commercial pact that will maintain zero import taxes on British medicine products being sold in the American market.
The Terms of the Accord
As part of the deal, the UK has committed to boost expenditure on drugs through the NHS. This move ensures that tariffs on these vital products will be held at zero for a period of 36 months.
This deal is in response to earlier threats to significantly raise tariffs on patented drug imports, with increases floated as high as double the cost.
"This agreement between the Britain strengthens the international landscape for innovative medicines and brings long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Economic Significance
Pharmaceuticals represent one of the UK's most significant exports to the US, which is clearly the primary market for major British pharmaceutical firms.
Export figures show that in the year leading up to last September, the UK sold drugs worth over eleven billion pounds to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement protects work, boosts capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several key commitments from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total public funding on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments exceeded 20%.
Industry Background
This agreement takes place against a protracted dispute between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by assertions that American patients were charged a premium for the same drugs than patients in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a share of its overall budget over the previous ten-year period.
